Soluble CD8 antigen, stimulated C-peptide and islet cell antibodies are predictors of insulin requirement in newly diagnosed patients with unclassifiable diabetes

Acta Diabetologica

Volumn 33, Issue 3, 1996, Pages 220-224

  Di Bonito, P ^a   De Bellis, A ^b   Capaldo, B ^c   Turco, S ^c   Corigliano, G ^d   Pace, E ^e   Bizzarro, A ^b  

^a Civil Hospital of Pozzuoli   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d AID (Italian Diabetes Association) Outpatient Service   (Italy)

^e CARDARELLI HOSPITAL   (Italy)

Author keywords

C peptide; Islet cell antibodies; Soluble CD8 antigen; Unclassifiable diabetes

Indexed keywords

C PEPTIDE; CD8 ANTIGEN; HEMOGLOBIN A; HLA ANTIGEN; INSULIN; PANCREAS ISLET CELL ANTIBODY;

ADOLESCENT; ADULT; AGE; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; DIABETES MELLITUS; FEMALE; HLA SYSTEM; HUMAN; INSULIN TREATMENT; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 0029857665     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02048547     Document Type: Article

References (23)

1. Landin-Olsson M, Karlsson A, Lernmark A, Sundkvist G et al, Islet and thyrogastric antibodies in 633 consecutive 15- to 34-yr-old patients in the diabetes incidence study in Sweden. Diabetes 41:1022-1027, 1992
2. Hother-Nielsen O, Faber O, Schwartz-Sorensen N, Beck-Nielsen H, Classification of newly diagnosed diabetic patients as insulin-requiring or non insulin-requiring based on clinical and biochemical variables. Diabetes Care 11:531-537, 1988
3. Landin-Olsson M, Nilsson KO, Lernmark A, Sundkvist G, Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetoiogia 33:56-568, 1990
4. Bottazzo GH Dean BM, McNally JM, McKay EH, Swift PGF, Gamble DR, In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 313:353-360, 1985
5. Santamaria P, Nakhleh RE, Sutherland DE, Barbosa J, Characterization of T lymphocytes infiltrating human pancreas allograft affected by isletitis and recurrent diabetes. Diabetes 41:53-61, 1992
6. Fujimoto J, Levy S, Levy R, Spontaneous release of the Leu-2 (T8) molecule from human T cells. J Exp Med 159:752-766, 1983
7. Tomkmson BE, Brown MC, Ip SH, Carrabis SH, Sullivan JL, Soluble CDS during T cell activation. J Immunol 142:2230-2236, 1989
8. Di Cesare E, Previti M, Ingemi C, Bagnato GF, Cucinotta D, High serum levels of soluble CDS in insulin-dependent diabetes. Clin Exp Immunol 95:283-286, 1994
9. WHO Study Group Report of Diabetes Mellitus, Technical Report 1985, series n727. WHO, Geneva, 1985
10. Cole R, Soldner J, Dunne P, Runn H, A rapid method for determination of glycosylated hemoglobin using high pressure liquid chromatography. Metabolism 27:289-301, 1978
11. Heding LS, Radio immunological determination of C-peptide in serum. Diabetologia 11:541-548, 1975
12. Terasaki PI, HLA DR joint report. In: Terasaki PI (eds) Histocompatibility testing. UCLA Tissue Typina Laboratory, Los Angeles, p 506, 1980
13. Boitard C, Bonifacio E, Bottazzo GF, Gleichmann H, Molenaar J, Immunology and Diabetes Workshop: report on the third international (stage 3) workshop of the standardisation of cytoplasmatic islet cell antibodies. Diabetoiogia 31:451-452, 1988
14. O'Rahiliy S, Spivey R, Holman RR, Nugent Z, Clark A, Turner RC, Type 2 diabetes early onset: a distinct clinical and genetic syndrome. Br Med J 294:923-928, 1987
15. Pagano GF, Cavallo-Perin P, Cavalot F, Dall'Omo Masciola P et al, Genetic, immunologic, and environmental heterogeneity of IDDM. Diabetes 36:859-863, 1987
16. Tarn AC, Dean BM, Schwartz G, Thomas JM, Ingram D, Bottazzo GF, Gale BAM, Predicting insulin-dependent diabetes. Lancet 1:845-850, 1988
17. Bonifacio E, Bingley PJ, Shattock M, Dean BM, Dunger D, Gale EAM, Bottazzo G, Quantification of islet cell antibodies and prediction of insulin dependent diabetes. Lancet 335:147-149, 1990
18. Di Mario U, Irvine W, Borsey D, Kyner J, Weston J, Galfo C, Immune abnormalities in diabetic patients not requiring insulin at diagnosis. Diabetologia 25:392-395, 1983
19. Christie M, Genovese S, Cassidy D, Bosi E, Brown T, Lai M, Bonifacio E, Bottazzo GF, Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes 43:1254-1259, 1994
20. Faber OK, Binder C, C-peptide response to glucagon. A test for the residual B-cell function in diabetes mellitus. Diabetes 26:605-610, 1977
21. Gjiessing HJ, Matzen LE, Faber OK, Froland A, Fasting plasma glucagon stimulated C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia 32:305-311, 1989
22. Madsbad S, Krarup T, McNair P, Christiansen C, Faber OK, Transbol I et al. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand 210:153-156, 1981
23. Koskinen P, Viikari J, Irjala K, Katola HL, Seppala P, C-peptide determination in the choice of treatment in diabetes mellitus. Scand J Clin Lab Invest 45:589-597, 1985